Announcements Trials
Browse Landscape

Phase

Phase 3 1Phase 2 1Phase 1 1

Status

Active not recruiting 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Gastrointestinal 1

Conditions

Stomach Neoplasms 7Colorectal Neoplasms 7Colonic Neoplasms 3Rectal Neoplasms 2Breast Neoplasms 2Squamous Cell Carcinoma of Head and Neck 1Pancreatic Neoplasms 1Nasopharyngeal Carcinoma 1Lung Neoplasms 1Klatskin Tumor 1Head and Neck Neoplasms 1Gallbladder Neoplasms 1Esophageal Neoplasms 1Epstein-Barr Virus Infections 1Cholangiocarcinoma 1Biliary Tract Neoplasms 1Bile Duct Neoplasms 1

Interventions

Gemcitabine 13Cisplatin 11durvalumab 7Oxaliplatin 5Capecitabine 5Fluorouracil 4S 1 (combination) 3Leucovorin 3Irinotecan 3zanidatamab 2gemcitabine-oxaliplatin regimen 2Trastuzumab 2trastuzumab deruxtecan 1pembrolizumab 1niraparib 1neratinib 1ivosidenib 1futibatinib 1envafolimab 1encorafenib 1binimetinib 1becatecarin 1Tegafur 1Pancreaticojejunostomy 1NUC-1031 1Folfox protocol 1Drug Therapy 1Chemotherapy, Adjuvant 1Carboplatin 1Albumin-Bound Paclitaxel 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 3 × Biliary Tract Neoplasms × Tegafur × Clear all
NCT06109779 2026-03-04

Rilvegostomig + Chemotherapy as Adjuvant Therapy for Biliary Tract Cancer After Resection (ARTEMIDE-Biliary01)

AstraZeneca

Phase 3 Active not recruiting
757 enrolled
Gastrointestinal

Bile Duct Neoplasms, Biliary Tract Neoplasms, Gallbladder Neoplasms, Cholangiocarcinoma, Klatskin Tumor

Data powered by HemOnc (CC BY 4.0) Colophon âš¡